The process of Takeda CEO Appointment culminated when Julie Kim became the new Representative Director, President and Chief Executive Officer of Takeda. She got the position after she was approved by the company’s shareholders at Takeda’s 150th Annual General Meeting of Shareholders in Osaka, Japan. At the shareholders’ meeting, Julie Kim was chosen as a new internal director to join the Board of Directors. Following that, the Board of Directors nominated her as the new Representative Director, President & CEO of the company. However, the outgoing President & CEO, Christophe Weber, decided to retire from the company and the Board after the meeting.
Chairman of the Board of Directors Meeting, Masami Iijima, congratulated Kim on the new position and assured them of success. Julie Kim talked about the future plans of the company and thanked all stakeholders for their support.
Chair of the Board of Directors Meeting, Masami Iijima, commented: “On behalf of Takeda’s Board of Directors, I would like to congratulate Julie Kim on becoming Takeda’s President and CEO. The Board of Directors is confident in Ms. Kim to drive executional excellence as Takeda launches a number of highly anticipated medicines and grows long-term shareholder value. The Board would like to thank Christophe Weber for his 12 years of extraordinary service to Takeda. He delivered global scale and an innovative pipeline, while strengthening Takeda’s reputation globally as a company built on integrity. We wish him all the best in the future.”
President & CEO, Julie Kim, commented: “It is a privilege and honor to lead Takeda and position the company for long-term profitable growth and increased patient impact. I would like to thank Christophe for his leadership over the last 12 years and in particular, his guidance during the transition period. I would also like to thank our shareholders, Mr. Iijima and the Board of Directors, including the six retiring external Directors, for their support. Going forward, I’m excited to partner with the elected Board to continue our important work for patients and other stakeholders. As we enter our next era, we have three major launches planned in the next 12 months and we are continuing to advance our robust pipeline of five additional highly innovative late-stage assets. Our growth roadmap built around our two strategic horizons positions us for a successful future for patients, our talented employees and shareholders.”
New Board Members Help Achieve Growth Objectives
Also, three additional external board members were elected as follows: Bruce Broussard, Koichiro Kimura, and Dr. Paul Stoffels. Together, they bring their skills to enhance the efforts of Takeda in terms of innovation in health care sector, corporate governance, development in pharma research and leadership in global markets. Moreover, the appointments for Takeda board of directors have been announced after the sessions of the board and its committees. In total, Takeda has 8 external directors out of 11 members of the board.
For more stories on technology leaders shaping the future of enterprise solutions, visit our CXO Insiders.
Source: Businesswire
